Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics Inc (NQ: DYN )

11.52 -0.06 (-0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 401,428
Open 11.69
Bid (Size) 10.75 (1)
Ask (Size) 12.34 (1)
Prev. Close 11.58
Today's Range 11.21 - 11.75
52wk Range 4.300 - 15.63
Shares Outstanding 56,338,214
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via Globe NewsWire
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-1.54%
-1.54%
1 Month
-15.48%
-15.48%
3 Month
-0.60%
-0.60%
6 Month
-9.29%
-9.29%
1 Year
+19.50%
+19.50%

More News

Read More
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via Globe NewsWire
What 4 Analyst Ratings Have To Say About Dyne Therapeutics
Via Benzinga
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
Via Benzinga
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via Globe NewsWire
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via Globe NewsWire
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
Dyne Therapeutics: Q3 Earnings Insights
Via Benzinga
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via Globe NewsWire
Dyne Therapeutics to Present at Investor Conferences in November
From Dyne Therapeutics, Inc.
Via Globe NewsWire
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via Globe NewsWire
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
From Dyne Therapeutics, Inc.
Via Globe NewsWire
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Dyne Therapeutics: Q2 Earnings Insights
Via Benzinga
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.